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The anti-inﬂammatory properties of TC-2559, an a4b2 nicotinic acetylcholine receptor (nAChR) agonist,
on cultured murine macrophages was investigated. TC-2559 suppressed the upregulation of CC-
chemokine ligand 3 (CCL3) and interleukin-1b (IL-1b) following lipopolysaccharide (LPS) treatment in
J774A.1 cells. TC-2559 inhibited the phosphorylation of signal transducer and activator of transcription 3
(pSTAT3) but not nuclear factor-kB p65 after LPS. Blockade of pSTAT3 by AG490 inhibited the upregu-
lation of CCL3 and IL-1b after LPS. In conclusion, TC-2559-driven a4b2 nAChR signaling suppressed the
upregulation of CCL3 and IL-1b by inhibiting pSTAT3 in inﬂammatory macrophages, resulting in the
suppression of neuropathic pain.
© 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Although macrophages normally play a central role in the im-
mune system, they often participate in the pathogenesis of various
diseases related to chronic inﬂammation (1). Neuroinﬂammation
due tomacrophage activation in injured peripheral nerves has been
characterized as a key component of intractable neuropathic pain
(2). We previously found that CC-chemokine ligand 3 (CCL3) and
interleukin-1beta (IL-1b), which are derived from classical inﬂam-
matorymacrophages, are responsible for peripheral sensitization in
neuropathic pain (3). Therefore, we hypothesized that the sup-
pression of inﬂammatory macrophages might be a novel thera-
peutic strategy for the treatment of neuropathic pain.
Recently, several lines of evidence demonstrated the impact of
nicotinic acetylcholine receptors (nAChRs) in the regulation of
macrophage functions (4). nAChRs are pentameric ligand-gated
cation channels widely distributed in several cell types that
maintain homeostasis in vivo (5). In the immune system, nAChR
signaling modulates the severity of intractable disease, such as
sepsis, arthritis, and other inﬂammatory syndromes, through sup-
pression of inﬂammatory macrophages and other leukocytes (4).: þ81 73 446 3806.
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d/4.0/).Our previous report demonstrated that the perineural adminis-
tration of nAChR ligands downregulated macrophage-derived in-
ﬂammatory factors in injured peripheral nerves to relieve
neuropathic pain in an experimental murine model (6). Moreover,
we found that the a4b2 nAChR subtype expressed in macrophages
has major roles in the suppression of peripheral neuro-
inﬂammation that facilitates neuropathic pain. The local injection
of an a4b2 nAChR agonist into the region surrounding an injured
nerve suppressed neuropathic pain induced by partial sciatic nerve
ligation in mice (7).
Nevertheless, the direct effects of a4b2 nAChR signaling on
neuropathic pain induced by inﬂammatorymacrophages are poorly
understood. Here, we determined the anti-inﬂammatory proper-
ties of TC-2559, an a4b2 nAChR agonist, using cultured murine
macrophages, which have similar features to neuropathic pain-
related macrophages in vivo.
Mouse macrophage J774A.1 cells (JCRB9108, HSRRB, Osaka,
Japan) were cultured in Dulbecco's modiﬁed Eagle's medium
(DMEM) containing 10% fetal bovine serum and 1% penicillin/
streptomycin at 37 C in an atmosphere of 5% CO2. TC-2559 difu-
marate (R&D Systems, Minneapolis, MN) and lipopolysaccharide
(LPS; SigmaeAldrich, Tokyo, Japan) were dissolved in sterile PBS,
and diluted with DMEM for use. For the experiments, cells werenese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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culture dish, and incubated with LPS and TC-2559 in DMEM
without serum.
For quantitative RT-PCR, cells were homogenized with TRIzol
reagent (Invitrogen, Carlsbad, CA), and 1 mg of the puriﬁed total
RNA was converted to cDNA by reverse transcription using M-MLV
reverse transcriptase (Promega, Madison, WI) and random primers
(Invitrogen). Ten nanograms of cDNA were used as a template for
quantitative real-time PCR with the KAPA SYBR FAST qPCR Kit
(Kapa Biosystems, Boston, MA) using the ECO Real-Time PCR Sys-
tem (As One, Osaka, Japan). Primers for CCL3 (50-CTG CCC TTG CTG
TTC TTC TC-30, 50-GTG GAA TCT TCC GGC TGT AG-30), IL-1b (50-AAA
GCT CTC CAC CTC AAT GG-30, 50-AGG CCA CAG GTA TTT TGT CG-30),
and GAPDH (50-GGG TGT GAA CCA CGA GAA AT-30, 50-ACT GTG GTC
ATGAGC CCT TC-30) were purchased fromHokkaido System Science
(Sapporo, Japan). Reactions were performed under the following
conditions: 95 C for 10 min, followed by 50 cycles of 95 C for 15 s
and 60 C for 60 s. The intensity of the ﬂuorescence of the inter-
calated SYBR Greenwas measured and normalized to GAPDH using
ECO software (As One).
For western blotting, collected cells were sonicated on ice. The
total protein concentration of the prepared extracts was measured
using a DC protein assay (Bio-Rad, Tokyo, Japan). Twenty micro-
grams of total protein were electrophoresed in 8e10% SDS-
polyacrylamide gel and transferred to a PVDF membrane. The
membrane was blocked with 5% nonfat dried milk for 2 h at 25 CFig. 1. Suppressive effects of TC-2559 on the expressions of CC-chemokine ligand 3 (CCL3) a
ml), TC-2559 (A, C; 20e500 mM, B, DeF; 500 mM), AG490 (50 mM), or their combination. mRN
RT-PCR. Each column shows the mean intensity ratio to GAPDH. Data are presented as theand incubated overnight in primary antibodies against signal
transducer and activator of transcription 3 (STAT3), phospho-STAT3
(pSTAT3), nuclear factor-kB p65 (NF-kB p65), and phospho-NF-kB
p65 (pp65). All primary antibodies were purchased from Cell
Signaling Technology (Danvers, MA). The membrane was washed
and incubated with secondary antibodies conjugated to horse-
radish peroxidase (Zymed, San Francisco, CA). After the incubation
with chemiluminescence reagent, immunoreactive bands were
detected using a Light-Capture system and CS analyzer software
(ATTO, Tokyo, Japan), and band intensities were quantiﬁed using
ImageJ software (National Institutes of Health, Bethesda, MD).
Data are presented as the mean ± SEM. Statistical analysis was
performed using one-way analysis of variance followed by Tukey's
multiple comparison test, or two-way analysis of variance followed
by Bonferroni's multiple comparison test as appropriate. Statistical
signiﬁcance was established at P < 0.05.
Quantitative RT-PCR analysis demonstrated that the mRNA ex-
pressions of CCL3 and IL-1bwere upregulated at 3 h after exposure
to LPS (50 ng/ml). Co-treatment of TC-2559 (20e500 mM) with LPS
for 3 h signiﬁcantly suppressed mRNA upregulation, in a dose-
dependent manner (Fig. 1A, B). Moreover, delayed treatment of
TC-2559 (500 mM) for 3 h after LPS also suppressed the upregula-
tion of CCL3 and IL-1b (Fig. 1C, D). Western blotting indicated that
pSTAT3 and pp65, which participate in the expression of inﬂam-
matory molecules (8,9), were observed after exposure to LPS
(Fig. 2A, B). TC-2559 (500 mM) inhibited the upregulation of pSTAT3nd interleukin-1b (IL-1b). J774A.1 cells were exposed to lipopolysaccharide (LPS; 50 ng/
A expression encoding CCL3 (A, C, E) and IL-1b (B, D, F) were evaluated by quantitative
mean ± SEM of 5e6 experiments. ***P < 0.001 vs Vehicle, ###P < 0.001 vs LPS.
Fig. 2. Inhibitory effects of TC-2559 on phosphorylation of signal transducer and activator of transcription 3 (pSTAT3). J774A.1 cells were exposed to lipopolysaccharide (LPS; 50 ng/
ml), TC-2559 (500 mM), AG490 (50 mM), or their combination. Protein expression of STAT3, pSTAT3, nuclear factor-kB p65 (p65), and phosho-p65 (pp65) were evaluated by western
blotting. Each column shows the mean intensity ratio of pSTAT3/STAT3 (A, C) or pp65/p65 (B, D, E). Data are presented as the mean ± SEM of 5e6 experiments. ***P < 0.001,
**P < 0.01, *P < 0.05 vs Vehicle, ###P < 0.001, ##P < 0.01 vs LPS.
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expression at 1 and 6 h after LPS (Fig. 2CeE). Co-treatment of
AG490 (50 mM), a Jak2-STAT3 pathway inhibitor, blocked the
upregulation of pSTAT3 but not pp65 (Fig. 2B, D), and prevented the
upregulation of CCL3 and IL-1b at 6 h after LPS (Fig. 1E, F).
Among the several types of nAChR subtype identiﬁed,
increasing attention has focused on the roles of a4b2 and a7
nAChRs in the neural and immune systems. Notably, a7 nAChR is
commonly characterized as an anti-inﬂammatory molecule, and a7
nAChR ligands improved chronic inﬂammatory diseases by the
suppression of macrophages (1,4). These effects of a7 nAChR li-
gands are thought to be, at least in part, mediated by inhibitory
effects against NF-kB p65 (8). However, it was reported that the
activation of Jak2-STAT3 signaling in macrophages was funda-
mentally important for the expression of several keymolecules that
facilitate neuropathic pain, such as CCL3 and IL-b (9,10). We alsoreported that treatment with AG490 diminished the pSTAT3-
dependent upregulation of CCL3 and other chemokines in
cultured murine macrophages (10), and prevented nerve injury-
induced tactile allodynia by inhibiting STAT3 activation in accu-
mulating macrophages (11).
The perineural administration of nicotine or TC-2559 to accu-
mulating macrophages relieved neuropathic pain, and these effects
were blocked by a selective a4b2 nAChR antagonist, suggesting that
a4b2 nAChR is a critical suppressor of inﬂammatory macrophages
in neuropathic pain (6,7). In this study, we showed for the ﬁrst time
that TC-2559 markedly suppressed the mRNA upregulation of in-
ﬂammatory molecules in cultured macrophages through pSTAT3
inhibition (Fig. 3). According to these results and general concepts
concerning the correlation of mRNA expression and protein syn-
thesis, we considered that TC-2559 can reduce the protein levels of
inﬂammatory molecules in macrophages. Therefore, the preventive
Fig. 3. Suppression of inﬂammatory factors by TC-2559 through pSTAT inhibition. LPS
activates Jak2-STAT3 and the NF-kB pathway downstream of toll-like receptor 4 (TLR4).
TC-2559-driven a4b2 nicotinic acetylcholine receptor (nAChR) signaling suppresses
the expression of CCL3 and IL-1b due to the inhibition of pSTAT3.
N. Kiguchi et al. / Journal of Pharmacological Sciences 128 (2015) 83e8686effects of nicotine and TC-2559 on neuropathic pain through a4b2
nAChR in vivo, might also be based on the reduction of inﬂamma-
tory molecules following pSTAT3 inhibition. This hypothesis was
conﬁrmed by other reports showing that the pSTAT3-dependent
expression of inducible nitric oxide was blocked by nicotine treat-
ment in cultured macrophages (12) and that the b2 nAChR subunit
attenuated tissue-resident macrophage activation by nicotine (13).
Importantly, the delayed treatment of TC-2559 after LPS also
suppressed the upregulated inﬂammatory factors secreted by
activated macrophages (Fig. 1C, D). These ﬁndings strongly conﬁrm
our previous in vivo study showing the relieving effects of nicotine
and TC-2559 on neuropathic pain were observed in not only in the
early phase but also during late phase administration after nerve
injury (7). The time-independent effectiveness of TC-2559 indicates
that a4b2 nAChR signalingmight be a novel therapeutic strategy for
the treatment of neuropathic pain. In addition, several reports
indicated that various nAChR ligands have analgesic effects on
physiological and inﬂammatory pain (14). Some of these agents
including TC-2559 can drive spinal inhibitory neurons in the dorsal
horn causing analgesia (15). Thus, nAChRs have a strong potential
to be novel analgesics, and anti-inﬂammatory mechanisms might
facilitate their therapeutic effects on neuropathic pain. Currently, a
detailed mechanism of nAChR-driven pSTAT3 inhibition is still
unclear, and should be clariﬁed in the future. All of these ap-
proaches should progress treatment for intractable neuropathic
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